Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 7/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335489 | 0.98 | GLA (0.50) | GLACNR2NCF1SMN1; SMN2NPC1 | |
| SCHEMBL9593490 | 0.94 | GLA (0.46) | GLACNR2NCF1SMN1; SMN2NPC1 | |
| SCHEMBL15144440 | 0.92 | CA9 (0.50) | GLACNR2NCF1SMN1; SMN2NPC1 | |
| SCHEMBL9052348 | 0.86 | GLA (0.40) | GLACNR2NCF1SMN1; SMN2LMNA | |
| SCHEMBL8751226 | 0.86 | GLA (0.42) | GLACNR2NCF1SMN1; SMN2L3MBTL1 | |
| SCHEMBL5441671 | 0.85 | CNR2 (0.50) | GLACNR2NCF1SMN1; SMN2NPC1 | |
| SCHEMBL3512796 | 0.84 | MAPT (0.43) | GLACNR2LMNAHTTMAPT | |
| SCHEMBL3539599 | 0.84 | MAPT (0.43) | GLACNR2LMNAHTTMAPT | |
| SCHEMBL3691836 | 0.84 | CNR2 (0.46) | CNR2NCF1SMN1; SMN2LMNAHTT | |
| SCHEMBL3685046 | 0.84 | HCRTR2 (0.44) | SMN1; SMN2LMNARAB9AL3MBTL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9061080-B2 | HER2 binding peptides labeled with aluminium-[18] fluoride complexed by NOTA | GE HEALTHCARE LIMITED (GB) | 2015-06-23 | — | — | US | disclosed |
| US-9061080-B2 | HER2 binding peptides labeled with aluminium-[18] fluoride complexed by NOTA | GE HEALTHCARE LIMITED (GB) | 2015-06-23 | — | — | US | disclosed |
| US-20130295010-A1 | HER2 BINDING PEPTIDES LABELLED WITH A 18F - CONTAINING ORGANOSILICON COMPOUND | GE HEALTHCARE LIMITED (GB) | 2013-11-07 | — | — | US | disclosed |
| US-20130295010-A1 | HER2 BINDING PEPTIDES LABELLED WITH A 18F - CONTAINING ORGANOSILICON COMPOUND | GE HEALTHCARE LIMITED (GB) | 2013-11-07 | — | — | US | disclosed |
| US-20130287685-A1 | HER2 BINDING PEPTIDES LABELED WITH ALUMINIUM-[18] FLUORIDE COMPLEXED BY NOTA | GE HEALTHCARE LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| US-20130287685-A1 | HER2 BINDING PEPTIDES LABELED WITH ALUMINIUM-[18] FLUORIDE COMPLEXED BY NOTA | GE HEALTHCARE LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| WO-2012087908-A1 | HER2 BINDING PEPTIDES LABELED WITH ALUMINIUM-[18] FLUORIDE COMPLEXED BY NOTA | GE HEALTHCARE LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087912-A1 | HER2 BINDING PEPTIDES LABELLED WITH A 18F - CONTAINING ORGANOSILICON COMPOUND | GE HEALTHCARE LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | CONCAT LP, A CALIFORNIA LIMITED PARTNERSHIP (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287685-A1 | HER2 BINDING PEPTIDES LABELED WITH ALUMINIUM-[18] FLUORIDE COMPLEXED BY NOTA | ERBB2, EGFR, ERBB3 | GLA 614/4885CNR2 4323/4885NCF1 383/4885 |
| US-20130295010-A1 | HER2 BINDING PEPTIDES LABELLED WITH A 18F - CONTAINING ORGANOSILICON COMPOUND | ERBB2, EGFR, ERBB3 | GLA 1516/4885CNR2 3920/4885NCF1 511/4885 |
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | SLC39A14, CHIA, CA2 | GLA 88/4885CNR2 4826/4885NCF1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.